Medley Pharmaceuticals Ltd

medleylab.com

“Medley” is a leading pharmaceutical company and one of the fastest growing pharmaceutical companies amongst the top 50 as per ORG-IMS

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RECURSION ACQUIRES VIUM STRENGTHENING ITS ATTEMPTS TO INDUSTRIALIZE DRUG DISCOVERY

Recursion, Vium | July 29, 2020

news image

Recursion, a digital biology company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research. Recursion’s acquisition of Vium signals continued and rapid integration of advanced technologies to grow its drug discovery pipeline of over 30 ...

Read More

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

news image

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More

Pharmacy Market

MARINUS PHARMACEUTICALS ANNOUNCES NEW METHOD OF USE PATENT GRANTED FOR IV GANAXOLONE BY USPTO IN STATUS EPILEPTICUS

Businesswire | June 26, 2023

news image

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including t...

Read More

Pharmacy Market

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

news image

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More
news image

RECURSION ACQUIRES VIUM STRENGTHENING ITS ATTEMPTS TO INDUSTRIALIZE DRUG DISCOVERY

Recursion, Vium | July 29, 2020

Recursion, a digital biology company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research. Recursion’s acquisition of Vium signals continued and rapid integration of advanced technologies to grow its drug discovery pipeline of over 30 ...

Read More
news image

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More
news image

Pharmacy Market

MARINUS PHARMACEUTICALS ANNOUNCES NEW METHOD OF USE PATENT GRANTED FOR IV GANAXOLONE BY USPTO IN STATUS EPILEPTICUS

Businesswire | June 26, 2023

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including t...

Read More
news image

Pharmacy Market

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More

Resources

resource image

Research, Business Insights

Navigating a Stringent Regulatory Landscape

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us